Airware's optical invention enables accurate monitoring of interstitial glucose. We end painful finger sticks for diabetics & deliver cost effective continuous monitoring now proven to lower HbA1c.

Funding completes proof of concept & secures worldwide filings beyond our 5 issued patents. Size reduction into portable monitors supports human testing. FDA approval per Class II 510(k) allows market entry under existing reimbursement codes.